摘要
目的研究蛋白激酶CK2β在肝细胞癌组织中的表达及临床意义,并探讨其表达与患者预后的关系。方法收集2012年1月-2013年6月于郑州大学第一附属医院肝胆胰外科确诊的127例肝细胞癌患者癌组织及癌旁组织,采用免疫组化法检测其CK2β的表达,分析癌组织中CK2β表达强度与肝癌患者临床特征的关系。另收集本院2018年3-6月期间手术切除的20例肝细胞癌癌组织、癌旁组织、肝硬化组织、正常肝组织标本并提取蛋白和mRNA,运用Westen Blot和real-time PCR检测其CK2β表达情况。多组间均数比较采用单因素方差分析,进一步两两比较采用Bonferroni检验,计数资料组间比较采用χ2检验。CK2β在肝细胞癌的表达差异与临床特征参数的关系采用Mann-Whitney U检验或Kruskal-Wallis H检验。生存分析采用Kaplan-Meier法,组间比较采用log-rank检验。结果 Westen Blot和real-time PCR结果证实CK2β在癌组织中表达率显著高于癌旁组织、肝硬化组织和正常肝组织(P值均<0. 05);癌旁及肝硬化组织中CK2β表达无差异(P值均> 0. 05),且均高于正常组织表达(P值均<0. 05)。免疫组化染色结果发现127例肝细胞癌患者的癌组织和癌旁组织中CK2β阳性表达率分别为85. 8%和63. 0%,差异有统计学意义(P <0. 001)。肝癌组织中CK2β的表达分布在不同年龄(Z=-2. 277,P=0. 023)、肝硬化有无(Z=-2. 144,P=0. 032)、不同肿瘤大小(Z=-2. 289,P=0. 004)、不同Edmondson-Steiner病理分级(χ2=8. 210,P=0. 016)的肝细胞癌患者中差异均有统计学意义。Kaplan-Meier生存曲线发现,CK2β表达强阳性组术后生存期均明显低于中阳性组、弱阳性组及阴性组(P值均<0. 001)。结论CK2β蛋白可能参与肝细胞癌的发生发展,其阳性表达与肝细胞癌患者预后有关。
ObjectiveTo investigate the expression and clinical significance of protein kinase CK2β in hepatocellular carcinoma (HCC) tissue and the association of CK2β expression with patient prognosis. MethodsHCC tissue and adjacent tissue samples were collected from 127 HCC patients Who were diagnosed in Department of Hepatopancreatobiliary Surgery, The first Affiliated Hospital of Zhengzhou University from Januany 2012 to June 2013, and immunohistochemistry was used to measure the expression of CK2β. The association of CK2β expression with clinical features of HCC patients was analyzed. A total of 20 HCC tissue samples, 20 adjacent tissue samples, 20 cirrhotic tissue samples, and 20 normal liver tissue samples were collected from March to June 2018 in our hospital, and Western blot and real-time PCR were used to measure the protein and mRNA expression of CK2β in these tissue samples. A one-way analysis of variance was used for comparison of means between multiple groups, and Bonferroni test was used for further comparison between two groups;the chi-square test was used for comparison of categorical data between groups. The Mann-Whitney U test or the Kruskal-Wallis H test was used to investigate the association of CK2β expression with clinical features. The Kaplan-Meier method was used for survival analysis, and the log-rank test was used for comparison between groups. ResultsWestern blot and real-time PCR showed that the expression rate of CK2β in HCC tissue was significantly higher than that in adjacent tissue, cirrhotic tissue, and normal liver tissue ( P <0.05);there was no significant difference in the expression of CK2β between adjacent tissue and cirrhotic tissue ( P >0.05), and the expression of CK2β in adjacent tissue and cirrhotic tissue was significantly higher than that in normal liver tissue ( P <0.05). Immunohistochemical staining showed that there was a significant difference in the positive rate of CK2β between HCC tissue and adjacent tissue in the 127 HCC patients (85.8% vs 63.0%, P <0.001). The
作者
梁润威
范正军
黄娟
孙涛
余祖启
LIANG Runwei;FAN Zhengjun;HUANG Juan(Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China)
出处
《临床肝胆病杂志》
CAS
北大核心
2019年第3期547-552,共6页
Journal of Clinical Hepatology
基金
河南省科技攻关项目(182102310143)
关键词
癌
肝细胞
蛋白质丝氨酸苏氨酸激酶
预后
carcinoma, hepatocellular
protein-serine-threonine kinases
prognosis
